Reinhard Dummer
University of Zurich · 2,788 works · 129,789 citations · h-index 153
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- High-throughput oncogene mutation profiling in human cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
- MEK1 mutations confer resistance to MEK and B-RAF inhibition